Satellos Bioscience Inc. (MSLE)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income | -22.03M |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MSLE
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (“DMD”). Satellos has generated evidence in preclinical models of DMD to support its hypothesis that correcting muscle stem cell polarity through treatment with SAT-3247 has the potential to restore skeletal muscle regenera... [Read more]
Financial Performance
Financial StatementsNews
Satellos initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Satellos (MSLE) with a Buy rating and $23 price target
Satellos initiated with an Outperform at Leerink
Leerink initiated coverage of Satellos (MSLE) with an Outperform rating and $20 price target The firm believes Satellos represents a differentiated early clinical-stage opportunity in Duchenne muscula...
Satellos has ‘catalyst-rich; 2026, says H.C. Wainwright
H.C. Wainwright analyst Arthur He placed an $11 price target on Buy-rated Satellos (MSLE) Bioscience, saying the company has a “catalyst-rich” 2026 with the TRAILHEAD and BASECAMP readouts. Published ...
Cantor starts Satellos with an Overweight on DMD therapy potential
As previously reported, Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Satellos (MSLE) with an Overweight rating and no price target SAT-3247 is an oral pill designed to improve mu...
Satellos initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Satellos (MSLE) with an Overweight rating.
Satellos Bioscience Inc. Common Stock trading resumes
10:09 EDT Satellos (MSLE) Bioscience Inc. Common Stock trading resumes
Satellos Bioscience Inc. Common Stock trading halted, volatility trading pause
10:04 EDT Satellos (MSLE) Bioscience Inc. Common Stock trading halted, volatility trading pause
Satellos presents interim SAT-3247 data at MDA Conference
Satellos (MSLE) Bioscience announced interim clinical and biomarker data for SAT-3247 at the Muscular Dystrophy Association, MDA, Clinical & Scientific Conference in Orlando, Florida. The data include...
Satellos price target raised to $40 from $5 at Oppenheimer
Oppenheimer raised the firm’s price target on Satellos (MSLE) to $40 from $5 and keeps an Outperform rating on the shares. The firm is updating its model for U.S. listing,…
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE), a clinical-stage biotechnology company developing life-improving medicines ...
Satellos Bioscience IPO Registration Document (F-10)
Satellos Bioscience has filed to go public with an IPO on the NASDAQ